Drug Trial Radar · NCT06357221
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Apr 8, 2024
Primary completion
Jul 18, 2024
Study completion Jul 18, 2024
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Apr 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen's efficacy will be conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.
Conditions
- Plaque Psoriasis
- Psoriasis
Interventions
CetaphilDrug
Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Psoriatic Body Surface Area Compared to BaselineTime frame: Baseline, Week 2, Week 4, Week 8
- Change in Target Lesion Severity Compared to BaselineTime frame: Baseline, Week 2, Week 4, Week 8
- Change of Physician Global Assessment Compared to BaselineTime frame: Baseline, Week 2, Week 4, Week 8
- Change in Skin Scaliness Measured by Macroscopic ImagingTime frame: Baseline, Week 2, Week 4, Week 8
- Change in Skin Smoothness Measured by Macroscopic ImagingTime frame: Baseline, Week 2, Week 4, Week 8
- Subject Treatment SatisfactionTime frame: Week 2
- Subject Treatment SatisfactionTime frame: Week 4
- Subject Treatment SatisfactionTime frame: Week 8
- Changes in Dryness Compared to Baseline [Tolerability Assessment]Time frame: Baseline, Week 2, Week 4, Week 8
- Change in Burning/Stinging Compared to Baseline [Tolerability Assessment]Time frame: Baseline, Week 2, Week 4, Week 8
- Change in Itching Compared to Baseline [Tolerability Assessment]Time frame: Baseline, Week 2, Week 4, Week 8
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Southeast Dermatology Specialists, LLC
Columbus, Georgia
Southeast Dermatology Specialists, LLC
Douglasville, Georgia
Dermatology Consulting Services
High Point, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.